---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-227950"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2024-09-27T23:59:59+00:00"
generated_at: "2026-05-31T01:09:20.824977+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CFO Julie Feder to depart Oct 25; VP Finance Amy Elazzouzi named interim CFO

## Summary
- CFO Julie Feder will resign effective Oct 25, 2024; no dispute or disagreement with company.
- Feder will provide consulting services through Dec 31, 2024, and receive severance of 10 months base salary.
- Amy Elazzouzi, VP Finance, appointed interim principal financial and accounting officer effective Oct 25.
- Elazzouzi's annual base salary increased to $360,000; eligible for 30% target bonus.
- Company will search for a permanent CFO during the interim period.

## SEC filing metadata
- accession: 0001193125-24-227950
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2024-09-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/d707178d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-227950
- JSON: https://secwatch.observer/filing/0001193125-24-227950.json
- Plain text: https://secwatch.observer/filing/0001193125-24-227950.txt

## Key facts
- Executive change
  Amy Elazzouzi was appointed as interim principal financial officer and interim principal accounting officer at Aura Biosciences, Inc..
  - Action: appointed
  - Role: interim principal financial officer and interim principal accounting officer
  source text: On September 25, 2024, the Board of Directors of the Company (the “Board”) designated Amy Elazzouzi, the Company’s Vice President, Finance, as the Company’s interim principal financial officer and interim principal accounting officer, in each case, effective on the Transition Date, to serve in such roles during the pendency of the Company’s search for a new Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm
- Executive change
  Julie Feder departed as Chief Financial Officer at Aura Biosciences, Inc..
  - Action: notified departure
  - Role: Chief Financial Officer
  source text: On September 23, 2024, Julie Feder notified Aura Biosciences, Inc. (the “Company”) of her departure from her role at the Company as an employee and Chief Financial Officer, effective as of October 25, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000119312524227950/0001193125-24-227950-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.